Janel Group LLC
JANL.PK operates in the Pharmaceuticals & Medical Research industry, focusing on the development, production, and distribution of pharmaceutical products.
Business. JANL.PK is a pharmaceutical company engaged in the research, development, and sale of pharmaceutical products. The firm operates within the broader healthcare sector, specifically focusing on pharmaceuticals and medical research activities. Specific details regarding its operating segments, headquarters location, and primary stock exchange listings are not available in the provided data. Consequently, the company is described at the industry level without geographic or segment-specific breakdowns.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsFY 2026 earnings (expected)2026-11-09 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
JANL.PK is a pharmaceutical company engaged in the research, development, and sale of pharmaceutical products. The firm operates within the broader healthcare sector, specifically focusing on pharmaceuticals and medical research activities. Specific details regarding its operating segments, headquarters location, and primary stock exchange listings are not available in the provided data. Consequently, the company is described at the industry level without geographic or segment-specific breakdowns.
JANL.PK has a liquidity position that is below the industry median, with a current ratio of 0.74, indicating that the company's current assets are less than its current liabilities. The company's cash and equivalents amount to $10.96 million, while its long-term debt is $18.56 million, resulting in a negative net cash position. The liquidity_fpt metric shows a moderate liquidity risk, with the company's operating cash flow of $43.07 million partially offsetting its debt obligations.
In terms of profitability, JANL.PK's return on equity (ROE) is 21.92%, which is significantly higher than the industry median, indicating strong returns for shareholders. However, the return on assets (ROA) is 3.31%, which is lower than the industry median, suggesting that the company is not efficiently utilizing its assets to generate profits. The gross profit margin is 31.33%, and the operating margin is 3.09%, both of which are below the industry median, indicating that the company is facing cost pressures.
JANL.PK's revenue is concentrated in a single business segment, with no disclosed geographic diversification. The company's revenue is entirely derived from its pharmaceutical operations, and there is no information available on geographic revenue distribution. This lack of diversification increases the company's exposure to market-specific risks.
The company's growth trajectory is modest, with no significant revenue growth reported in the latest financial period. The operating income has remained relatively flat, and the net income has slightly declined. The capital expenditure is negative, indicating that the company is not investing in new assets, which may limit its long-term growth potential.
The risk assessment for JANL.PK indicates a medium liquidity risk and a low dilution risk. The company's key financial flags include a negative net cash position after subtracting total debt, which could impact its ability to meet short-term obligations. The dilution potential is low, as the number of shares outstanding is the same for both basic and diluted shares, indicating no imminent threat of share dilution.
Recent events related to JANL.PK include the latest financial filing, which provides an updated view of the company's financial position. There are no recent earnings call transcripts or other material events disclosed in the available data.
- JANL.PK has a strong return on equity (21.92%) but a weak return on assets (3.31%), indicating inefficiencies in asset utilization.
- The company's liquidity position is weak, with a current ratio of 0.74 and a negative net cash position.
- Revenue is concentrated in a single business segment, with no geographic diversification disclosed.
- Growth is limited, with flat operating income and a negative capital expenditure.
- The company has a low dilution risk, with no difference between basic and diluted shares outstanding.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- JANL.PK Market data — financials · 2026-05-28
Ownership & reference
Insider activity
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Total assets (YoY) (2025-12-31 vs 2024-12-31): 58.3%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 61.3%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 18.2%Derived (calculated)
- Current ratio (FY 2025-12-31): 0.74xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): 6.24xDerived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 185.8%Derived (calculated)
- Total assets (annual): USD 176.12MSEC XBRL filing
- Long-term debt (annual): USD 9.12MSEC XBRL filing
- Current assets (annual): USD 94.91MSEC XBRL filing
- Shares outstanding (annual): 1.19MSEC XBRL filing
- Current liabilities (annual): USD 127.95MSEC XBRL filing
- Cash & equivalents (annual): USD 6.72MSEC XBRL filing
- Total liabilities (annual): USD 147.22MSEC XBRL filing
- Shareholders' equity (annual): USD 23.59MSEC XBRL filing
- Operating income (YoY) (2025-09-30 vs 2024-09-30): 71.2%Derived (calculated)
- Gross profit (YoY) (2025-09-30 vs 2024-09-30): 11.3%Derived (calculated)
- Gross margin (FY 2025-09-30): 31.3%Derived (calculated)
- Net margin (FY 2025-09-30): 2.7%Derived (calculated)
- EPS (basic) (YoY) (2025-09-30 vs 2024-09-30): 2,131.6%Derived (calculated)
- Revenue (YoY) (2025-09-30 vs 2024-09-30): 13.2%Derived (calculated)
- Net income (YoY) (2025-09-30 vs 2024-09-30): 926.7%Derived (calculated)
- Operating cash flow (YoY) (2025-09-30 vs 2024-09-30): 530.4%Derived (calculated)
- Cost of revenue (YoY) (2025-09-30 vs 2024-09-30): 14.1%Derived (calculated)
- EPS (diluted) (YoY) (2025-09-30 vs 2024-09-30): 2,216.7%Derived (calculated)